Agarwal, S., Wagner, M. K., & Mion, M. (2024). Psychological and behavioral dimensions in cardiac arrest survivors and their families: A state-of-the-art review. Neurotherapeutics, e00509. https://doi.org/10.1016/j.neurot.2024.e00509

Chang, H., Lee, K. J., Park, M., Woo, H.-N., Kim, J. H., Kang, I. K., Park, H., Chon, C. H., Lee, H., & Jung, H. H. (2024). Cross-species RNAi therapy via AAV delivery alleviates neuropathic pain by targeting GCH1. Neurotherapeutics, e00511. https://doi.org/10.1016/j.neurot.2024.e00511

Kuo, S.-H. (2023). GABAA Receptor Subtype Specificity in Essential Tremor. Neurotherapeutics, 20(2), 372–374. https://doi.org/10.1007/s13311-023-01341-z

Benatar, M., Wuu, J., Andersen, P. M., Bucelli, R. C., Andrews, J. A., Otto, M., Farahany, N. A., Harrington, E. A., Chen, W., Mitchell, A. A., Ferguson, T., Chew, S., Gedney, L., Oakley, S., Heo, J., Chary, S., Fanning, L., Graham, D., Sun, P., … Fradette, S. (2022). Design of a Randomized, Placebo-Controlled, Phase 3 Trial of Tofersen Initiated in Clinically Presymptomatic SOD1 Variant Carriers: the ATLAS Study. Neurotherapeutics, 19(4), 1248–1258. https://doi.org/10.1007/s13311-022-01237-4

Chen, X., Zhang, J., Wu, Y., Tucker, R., Baird, G. L., Domonoske, R., Barrios-Anderson, A., Lim, Y.-P., Bath, K., Walsh, E. G., & Stonestreet, B. S. (2022). Inter-alpha Inhibitor Proteins Ameliorate Brain Injury and Improve Behavioral Outcomes in a Sex-Dependent Manner After Exposure to Neonatal Hypoxia Ischemia in Newborn and Young Adult Rats. Neurotherapeutics, 19(2), 528–549. https://doi.org/10.1007/s13311-022-01217-8